文献速递骨肿瘤关节外科

评估聚乙烯、聚醚醚酮与金属对金属锁定机制在模块化通用肿瘤与翻修系统膝关节重建中的生存情况:来自MUTARS欧洲骨科登记的研究

Evaluating polyethylene, polyether-ether-ketone, and metal-on-metal locking mechanism survival in Modular Universal Tumour and Revision System knee reconstructions for oncological indications : insights from the MUTARS Orthopedic Registry Europe.
PubMed 文献 · Bone Joint J · 2025-02-01

基于MUTARS欧洲骨科登记,回顾316例1995年12月至2023年1月因肿瘤指征行MUTARS膝关节置换的患者,中位随访7.9年。因磨损或锁定机制断裂导致症状性不稳的翻修累积发生率在PEEK组高于PE组和MoM组,PEEK与MoM相对于PE的病因特异性风险比分别为3.6和3.2。结论认为假体材料变更未降低锁定机制失败翻修风险,且未发现其他患者或假体相关危险因素。

要点

  • 34例(11%)发生因磨损或锁定机制断裂导致的症状性不稳:PE 9%(4/45)、PEEK 20%(9/44)、MoM 9%(21/227)。
  • 以PE为参照,PEEK的病因特异性风险比为3.6(95%CI 1.1至11.9;p=0.036),MoM为3.2(95%CI 1.1至9.5;p=0.043)。
  • 年龄、BMI、切除长度和关节外切除与锁定机制翻修时间无关。

核心结论

  • 假体材料变更未降低锁定机制失败的翻修风险。
  • 除锁定机制材料外,未发现其他患者或假体相关的锁定机制失败危险因素。
  • 作者认为需要改进锁定机制,因为翻修使患者面临严重继发并发症风险。

研究设计与样本

  • 使用MUTARS欧洲骨科登记进行回顾性审查,纳入316例因肿瘤指征行MUTARS膝关节置换的患者,54%为男性(n=170),中位年龄44岁(IQR 23至61),手术时间在1995年12月至2023年1月之间。
  • 最低随访12个月,中位随访7.9年(IQR 3.3至13.0)。
  • 采用竞争风险模型估计首次锁定机制翻修的累积发生率,以死亡和因其他原因翻修为竞争事件。
  • 采用单因素病因特异性风险回归模型评估可能的危险因素。

主要发现

  • 因磨损(n=20)或断裂(n=14)导致的铰链或锁定机制症状性不稳发生于34例患者(11%):PE为9%(n=4/45),PEEK为20%(n=9/44),MoM为9%(n=21/227)。
  • 因磨损或锁定机制断裂导致不稳的翻修累积发生率在2年、5年和10年分别为:PE为0%、5%(95%CI 1至15)和5%(95%CI 1至15);PEEK为5%(95%CI 1至14)、14%(95%CI 5至26)和16%(95%CI 7至29);MoM为0%、3%(95%CI 1至6)和10%(95%CI 5至16)。
  • 以PE为参照,PEEK和MoM的病因特异性风险比分别为3.6(95%CI 1.1至11.9;p=0.036)和3.2(95%CI 1.1至9.5;p=0.043)。
  • 年龄、BMI、切除长度和关节外切除与锁定机制翻修时间无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Over time, the locking mechanism of Modular Universal Tumour and Revision System (MUTARS) knee arthroplasties changed from polyethylene (PE) to polyether-ether-ketone Optima (PEEK) and metal-on-metal (MoM) in an attempt to reduce the risk of mechanical failure. In this study, we aimed to assess the cumulative incidence of locking mechanism revision for symptomatic instability by type of material, and assess potential associated risk factors. METHODS: The MUTARS Orthopaedic Registry Europe was used for a retrospective review of 316 patients (54% male (n = 170), median age 44 years (IQR 23 to 61)) who underwent a MUTARS knee arthroplasty for oncological indications between December 1995 and January 2023. The minimum follow-up was 12 months, and the median follow-up was 7.9 years (IQR 3.3 to 13.0). A competing risk model was used to estimate the cumulative incidence of first locking mechanism revision with death and revision for any other reason as competing events. Possible risk factors were assessed employing a univariate cause-specific hazards regression model. RESULTS: Symptomatic instability of the hinge or locking mechanism due to wear (n = 20) or breakage (n = 14) occurred in 34 patients (11%): 9% of PE (n = 4/45), 20% of PEEK (n = 9/44), and 9% of MoM locking mechanisms (n = 21/227). The cumulative incidences of revision for instability due to wear or locking mechanism breakage at two, five, and ten years were 0%, 5% (95% CI 1 to 15), and 5% (95% CI 1 to 15) for PE, 5% (95% CI 1 to 14), 14% (95% CI 5 to 26), and 16% (95% CI 7 to 29) for PEEK, and 0%, 3% (95% CI 1 to 6), and 10% (95% CI 5 to 16) for MoM. With PE as the reference category, the cause-specific hazard ratio for PEEK and MoM were 3.6 (95% CI 1.1 to 11.9; p = 0.036) and 3.2 (95% CI 1.1 to 9.5; p = 0.043), respectively. Age, BMI, resection length, and extra-articular resections were not associated with the time to locking mechanism revision. CONCLUSION: Alterations in prosthetic materials have not decreased the revision risk for locking mechanism failure. Besides locking mechanism material, no other patient- or prosthesis-related risk factors for locking mechanism failure were identified. Improvement of the locking mechanism is warranted since revision exposes patients to the risk of serious secondary complications.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Evenhuis RE, Bus MPA, van Nes J, et al. Evaluating polyethylene, polyether-ether-ketone, and metal-on-metal locking mechanism survival in Modular Universal Tumour and Revision System knee reconstructions for oncological indications : insights from the MUTARS Orthopedic Registry Europe. Bone Joint J. 2025. PMID: 39889752. doi:10.1302/0301-620X.107B2.BJJ-2024-0623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。